Home > Press Room > Events > Going Public – Biotech Leaders On their Path To Funding
  • Print
  • Send to email


Going Public – Biotech Leaders On their Path To Funding

Location: CCIT, 675 US Highway One, North Brunswick, New Jersey 08902

Date:  Monday, April 24, 2017
Time: 5:00 pm - 7:00 pm

This event hosted in partnership with:


Leaders of New Jersey’s publicly traded biotech firms will tell their story and provide guidance and recommendations on going public as a path to funding.  

Register now and join us for networking and guidance from Scott Jackson, past CEO of Celator recently acquired by Jazz Pharmaceuticals, and Dan O’Connor, CEO of Advaxis and Kathleen Bloch, CFO of Cytosorbents. 

The panel will showcase biotech leaders on their respective paths to success, including insights into their strategy and decisions faced along the way to their companies becoming public.

Featured Speakers:


Daniel O’Connor, President, Chief Executive Officer and Director, Advaxis, Inc. 

Daniel O’Connor is President, Chief Executive Officer and Director of Advaxis, Inc., a Princeton-based clinical stage biotechnology company that is developing cancer immunotherapies. As CEO, Mr. O’Connor has led the transformation of Advaxis into a leading cancer immunotherapy company.  In 2017, Mr. O’Connor was appointed Vice Chairman of BioNJ, leveraging his experience to guide and support the organization’s mission of fostering the innovation of research-based life science companies in the New Jersey region.


Kathleen Bloch, MBA, CPA, Chief Financial Officer, CytoSorbents Corporation 

Ms. Bloch has more than 20 years of executive financial experience at both public and private companies. From 2008 to 2010, she served as the Chief Operating Officer of PC Group, Inc., where she was hired as CFO in 2007.   She holds a Master of Business Administration degree and a Bachelor of Science Accounting degree from LaSalle University.  CytoSorbents Corporation (NASDAQ: CTSO) is a critical care immunotherapy company, which engages in blood purification to control deadly inflammation in critically-ill and cardiac surgery patients. Its products include cytosorb, contrastsorb, vetresq, hemodefend, and drugsorb.


Scott Jackson, Former CEO, Celator Pharmaceuticals 

When Scott Jackson became CEO of Celator Pharmaceuticals, a new treatment for a blood cancer called acute myeloid leukemia (AML) hadn’t been approved in decades. Under Jackson’s leadership, Celator demonstrated in a Phase 3 clinical trial that its drug combination product called VYXEOS™ produced an overall survival benefit compared to the current standard of care (known as 7+3, which was first published in the 1970s) in high-risk AML patients. The results caught the attention of pharmaceutical companies, in particular Jazz Pharmaceuticals plc, which acquired Celator for about $1.5 billion. At the time, Celator was about to embark on the process of seeking FDA approval, which presented an attractive opportunity for the Irish pharmaceutical company.  Mr. Jackson is no longer with the company, as Celator is now an indirect wholly owned subsidiary of Jazz.


Commercialization Center for Innovative Technologies (CCIT)
675 US Highway One, North Brunswick, New Jersey 08902

CCIT is one of the more significant incubation facilities in the nation dedicated to life sciences and biotechnology companies.  CCIT is located at the Technology Centre of New Jersey, a 75 acre life sciences research park in North Brunswick, NJ.